Topic: mergers and acquisitions
As Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest.
As the Federal Trade Commission issued a "second request" for more info on the deal, U.K. antitrust watchdogs opened their own probe.
Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Just weeks after selling its share in Brammer Bio in a $1.7 billion deal, Ampersand has an agreement to buy another CDMO with viral vector expertise.
Evoke is bulking up it communications practice with a big acquisition just days after tapping an experienced leader to spearhead its New York outpost.
Catalent's newly acquired Paragon Bioservices will expand its capacity to as much as 425,000 square feet to manufacture therapies for Sarepta.
Takeda, in its first year counting the Shire business, managed to turn up revenue growth. But the upcoming fiscal year could be a different story.
Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.
Ajinomoto Bio-Pharma Services has concluded a deal that will allow the CDMO to operate in the gene therapy space.
In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.